<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial regimens for acute bacterial rhinosinusitis in children&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial regimens for acute bacterial rhinosinusitis in children<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial regimens for acute bacterial rhinosinusitis in children<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Indication</td> <td class="subtitle1">Initial therapy</td> <td class="subtitle1">Second-line therapy*</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Outpatient therapy</td> </tr> <tr> <td class="indent1">Mild/moderate disease<sup>¶</sup></td> <td> <p><strong>Preferred:</strong> Amoxicillin-clavulanate 45 mg/kg<sup>Δ</sup> per day orally divided in 2 doses (maximum 1.75 g/day)</p> <strong>Alternative:</strong><sup>◊</sup> Amoxicillin 90 mg/kg per day orally divided in 2 doses (maximum 4 g/day)</td> <td> Either: <ul class="decimal_heading"> <li>Amoxicillin-clavulanate 90 mg/kg<sup>§</sup> per day orally divided in 2 doses (maximum 4 g/day), or</li> <li>Ceftriaxone 50 mg/kg once per day IV or IM (maximum 4 g/day) for 1 to 3 days followed by appropriate oral regimen</li> </ul> </td> </tr> <tr> <td class="indent1" rowspan="3">Severe disease or risk for antibiotic resistance<sup>¶</sup></td> <td> <strong>Preferred:</strong> Amoxicillin-clavulanate 90 mg/kg<sup>§</sup> per day orally divided in 2 doses (maximum 4 g/day)</td> <td> One of the following: <ul class="decimal_heading"> <li>Ceftriaxone 50 mg/kg once per day IV or IM (maximum 4 g/day) for 1 to 3 days followed by appropriate oral regimen, or</li> <li>Cefpodoxime 10 mg/kg per day orally divided in 2 doses (maximum 400 mg/day), or</li> <li>Cefdinir 14 mg/kg per day orally divided in 1 or 2 doses (maximum 600 mg/day), or</li> <li>Levofloxacin<sup>¥</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</li> </ul> </td> </tr> <tr> <td> <strong>Alternatives:</strong><sup>◊</sup> <ul class="decimal_heading"> <li>Cefpodoxime 10 mg/kg per day orally divided in 2 doses (maximum 400 mg/day), or</li> <li>Cefdinir 14 mg/kg per day orally divided in 1 or 2 doses (maximum 600 mg/day), or</li> </ul> </td> <td> Either: <ul class="decimal_heading"> <li>Amoxicillin-clavulanate (depending upon the rationale for initial therapy with cefpodoxime or cefdinir) 90 mg/kg<sup>§</sup> per day orally divided in 2 doses (maximum 4 g/day), or</li> <li>Levofloxacin<sup>¥</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</li> </ul> </td> </tr> <tr> <td> <ul> <li>Levofloxacin<sup>¥</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</li> </ul> </td> <td>Inpatient therapy (see below)</td> </tr> <tr> <td class="indent1">Penicillin allergy: Immediate (eg, anaphylaxis) or serious delayed reaction (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis)</td> <td> <ul> <li>Levofloxacin<sup>¥</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</li> </ul> </td> <td>Inpatient therapy (see below)</td> </tr> <tr> <td class="indent1">Penicillin allergy: Mild delayed reaction</td> <td> <ul> <li>Cefpodoxime 10 mg/kg per day orally divided in 2 doses (maximum 400 mg/day), or</li> <li>Cefdinir 14 mg/kg per day orally divided in 1 or 2 doses (maximum 600 mg/day)</li> </ul> </td> <td> <ul> <li>Levofloxacin<sup>¥</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</li> </ul> </td> </tr> <tr> <td class="indent1">Vomiting</td> <td> <ul> <li>Ceftriaxone 50 mg/kg per day IV or IM once (maximum 1 g/day), followed 24 hours later by appropriate oral therapy</li> </ul> </td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Inpatient therapy</td> </tr> <tr> <td class="indent1">ABRS requiring hospitalization<sup>¶</sup></td> <td> <ul> <li>Ampicillin-sulbactam 200 to 400 mg/kg per day IV divided every 6 hours (maximum 8 g ampicillin component/day), or</li> <li>Ceftriaxone 50 mg/kg per day IV divided every 12 hours (maximum 4 g/day), or</li> <li>Levofloxacin<sup>¥</sup> 10 to 20 mg/kg per day IV divided every 12 or 24 hours (maximum 500 mg/day)</li> </ul> </td> <td> <ul> <li>Addition of vancomycin (60 mg/kg per day IV) divided every 6 hours (maximum 4 g/day)<sup>†</sup> and possibly,</li> <li>Metronidazole** (30 mg/kg per day IV) divided every 6 hours (maximum 4 g/day)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp pediatric drug monograph for renal dose adjustments.</div><div class="graphic_footnotes"><p>IV: intravenously; IM: intramuscularly; ABRS: acute bacterial rhinosinusitis.</p>
<p>* Second-line therapies are indicated for children who worsen within three days or fail to improve after three days of initial therapy and in whom no pathogen is identified. If a pathogen is identified, antimicrobial therapy should be adjusted according to susceptibilities.</p>
<p>¶ Refer to UpToDate topic on treatment of acute bacterial rhinosinusitis in children for definitions.</p>
<p>Δ Based on amoxicillin component; in the United States, use 200 or 400 mg/5 mL suspension or 200 or 400 mg chewable tablet for appropriate clavulanate ratio.</p>
<p><span class="lozenge">◊</span> Alternative regimens may not cover resistant pathogens as well as the suggested initial regimen.</p>
<p>§ Based on amoxicillin component; in the United States, use 600 mg/5 mL suspension or 1000 mg/62.5 mg extended-release tablet for appropriate clavulanate ratio.</p>
<p>¥ Levofloxacin should be reserved for cases in which there is no other safe and effective alternative.</p>
<p>† Individualize vancomycin dose and interval based on serum concentration monitoring, when indicated.</p>
	
	** Metronidazole may be warranted for anaerobic coverage.</div><div class="graphic_reference">References:
	<ol>
<li>Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.</li>
<li>Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics 2016; 138.</li>
</ol></div><div id="graphicVersion">Graphic 83454 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
